CANCER

Bloodwise 32
STRATEGIC REPORT
FINANCIAL REVIEW
Your support
162 x 235 45mm straight flap.pdf 1 21/10/2014 09:26
INCOME
Following an exceptional year for generating income
in FY14, when we achieved an increase of 19%
in voluntary income, we found FY15 much more
challenging in some areas of fundraising. Our total
income of £20.6 million was £1.1 million (-5%) below
FY14 (£21.7 million) and both voluntary and legacy
income were down on the previous year.
Printed using FSC certified paper, using fully sustainable, vegetable oil-based inks,
power from 100% renewable resources and waterless printing technology. Please recycle.
If undelivered please return to: Leukaemia & Lymphoma Research, 39-40 Eagle Street,
London WC1R 4TH. Registered charity 216032 (England & Wales) SC037529 (Scotland)
LIFE IS MADE
OF LITTLE
MOMENTS
We continue to demonstrate strength in our
fundraising engagement with the UK public: as a
result growth in our small gift teams including our
regional fundraising, sports events and individual
giving was 11%.
Unfortunately this was offset by a significant
reduction in income from the large gifts teams,
including corporate, trusts and high value
partnerships of 43%. During the year we had hoped
to scope opportunities for statutory funding; this
proved more challenging than we had anticipated
and will require further exploration.
Our cost of generating funds increased by £348,000
in FY15. During the year we made planned new
investments in generating funds as we began to
implement a new fundraising strategy. This included
the diversification of our sports events portfolio with
new events including the Velothon in Wales; the World
Triathlon Series and some additional Ironman events.
We also began a restructure of our Major Funding
teams and tested some Individual Giving initiatives.
In the short term this has reduced our fundraising
efficiency, but this is in expectation of future growth
in income. Because of the substantial increase in
charitable expenditure, the proportion of total
expenditure represented by the cost of generating
funds fell from 22.1% to 19.9% (see page 4).
Our 2014 Winter Appeal
Take this moment.
Make it count.
INDIVIDUAL GIVING
Where for many charities individual giving is the
bedrock of fundraised income, this is potentially an
unrealised opportunity for our charity. We haven’t
adopted some of the traditional approaches to
individual giving such as direct mail, face-to-face
and telephone fundraising.
WAPOST/111401
{Additional Address 2}
{City}
{Postcode}
{Street Address}
{Additional Address 1}
{Individual Prefix} {First Name} {Last Name}
Philosophically we don’t think it’s a good idea to
interrupt the lives of cancer patients and their
families, but at the same time we need to give people
better opportunities to support us on a regular basis.
During the year we piloted a Christmas appeal and have
plans for a further late Spring appeal. There’s no doubt
that we’ll need to be innovative and engaging if we’re
to accelerate growth in this area. In FY15 we raised £0.5
million from individual giving (FY14: £0.3 million).
xxxxxxx
Bloodwise trading as Leukaemia & Lymphoma Research Company limited by guarantee 738089
Registered charity 216032 (England & Wales) SC037529 (Scotland)